Pharmaceutical Technology

JANUARY 30, 2023

These are forecast to generate $264 billion in sales between 2021 and 2028. Comirnaty, which was first approved in the UK by an Emergency Use Approval (EUA) from the Medicines and Healthcare products Regulatory Agency (MHRA) on December 2, 2020, is currently the leading prophylactic vaccine with 2021 sales of $41.5

Sales 52

Sales Leads Competition Medicine 52

Pharmaceutical Technology

JANUARY 25, 2023

Currently, Spikevax is the second bestselling Covid-19 vaccine behind Pfizer’s Comirnaty, which is in the leading position, with forecast sales of $37bn in 2022. Despite this, Spikevax vaccine market share is expected to decline from 30% in 2022 to just 16% by the end of 2028.

Competition 59

Competition Sales Marketing Leads 59

European Pharmaceutical Review

AUGUST 22, 2023

Between 2023-2028, the global bioprocess containers market is anticipated to see strong growth. This can therefore lead to inefficiencies and additional costs. A market report by Research and Markets considers this to be mainly due to the higher demand for automation and machine learning in the biopharmaceutical industry.

Marketing 98

Marketing Manufacturing Leads Pharmaceutical 98

World of DTC Marketing

SEPTEMBER 9, 2021

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Healthcare 222

Healthcare Healthcare Government Insurance 222

Pharmaceutical Technology

MAY 16, 2023

This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’. Johnson & Johnson maintained its leading position despite a decline of 12.8%

Marketing 52

Marketing Sales Pharma Leads 52

Pharmaceutical Technology

SEPTEMBER 15, 2022

According to GlobalData’s report, Coronavirus Disease 2019 (Covid-19) Analyst Consensus Sales Analysis and Forecast, H1 2022 , Comirnaty is the leading prophylactic Covid-19 vaccine and recorded sales of $41.3bn in 2021. AbbVie reported a 22.7% Bristol Myers Squibb (BMS) documented a 9.1%

Sales 108

Sales Competition Pharmaceutical Pharmaceutical research 108

Pharmaceutical Technology

NOVEMBER 8, 2022

These acquisitions could possibly add a minimum of $1bn in sales of Viatris by 2028. This will form the foundation to establish a leading international ophthalmology franchise, expediting work for addressing the unmet needs in the area of ophthalmic diseases. Famy Life Sciences has an ophthalmology portfolio that complements Viatris.

Food and Drug Administration 59

Food and Drug Administration Leads Food Pharma 59

Pharmaceutical Technology

MAY 19, 2023

EyePoint Pharmaceuticals will also receive potential royalties on the combined net sales of Iluvien and Yutiq in the US from 2025 to 2028.

Food and Drug Administration 52

Food and Drug Administration Pharmaceutical Food Sales 52

European Pharmaceutical Review

FEBRUARY 8, 2023

It is set to retain its market-leading position as the most lucrative CD19 CAR-T agent in NHL, with annual sales reaching $1.7 Breyanzi is approved for DLBCL, and a label expansion is anticipated for expansions into marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) in 2026 and 2028, respectively.

Marketing 98

Marketing Sales Physicians Patients 98

World of DTC Marketing

MARCH 17, 2021

Fierce Pharma just reported, “a big question hanging over AbbVie CEO Richard Gonzalez is whether he can lead the Illinois pharma safely through the patent cliff of its revenue cornerstone Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.

Pharma 186

Pharma Competition Prescription Sales 186

Pharmaceutical Technology

MAY 26, 2023

These figures are only expected to grow in the coming years, with sales forecasted to reach over $150 billion by 2028. Checkpoint modulators and cell therapies lead the way in the pre-registration stage, which features no cancer vaccines and oncolytic virus-focused therapies, she added.

Marketing 105

Marketing Physicians Insurance Pharmaceutical 105

European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

Biopharma 98

Biopharma Marketing Sales Medicine 98

Pharmaceutical Technology

AUGUST 16, 2022

In 2019, Daiichi Sankyo entered a global development and commercialisation agreement with AstraZeneca for Daiichi Sankyo’s lead antibody-drug conjugate (ADC), Enhertu (trastuzumab deruxtecan), in a deal worth $6.9bn. GlobalData estimates that global annual sales for datopotamab deruxtecan in the NSCLC setting will exceed $500m in 2028.

Food and Drug Administration 59

Food and Drug Administration Sales Patients Food 59

Pharmaceutical Technology

DECEMBER 16, 2022

This therapy is currently in Phase II development and is expected to launch in the US and 5EU in 2027 and 2028, respectively. GlobalData’s report also covers a third pipeline candidate, quinagolide, a dopamine receptor antagonist being developed by Ferring Pharmaceuticals.

Marketing 59

Marketing Side effects Sales Safety 59

PM360

SEPTEMBER 21, 2023

CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program. Some stakeholders have expressed concern that negotiation could lead to a reduction in drug innovation. Additionally, highly competitive classes, such as rapid-acting insulin and immunologics are included on the selected drug list.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

JUNE 24, 2024

By analyzing, sifting, and sorting patient data, AI tools enable healthcare providers to significantly improve their interactions with patients, ultimately leading to enhanced satisfaction and better healthcare outcomes. million by 2028. Ultimately, these advancements lead to enhanced patient care and outcomes.

Physicians 59

Physicians Patients Healthcare Provider Healthcare 59

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%). Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 Proper research and investment in this field can lead to treating the disease efficiently. The Cancer Immunotherapy Market Size is estimated to reach $152.6 It is further expected to reach USD 14,505 million in 2030.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Medico Reach

MARCH 24, 2023

billion by 2028. Nanotechnology By 2028, the Nanotechnology Medicines Delivery Market is expected to be $141.2 Proper research and investment in this field can lead to treating the disease efficiently. The Cancer Immunotherapy Market Size is estimated to reach $152.6 It is further expected to reach USD 14,505 million in 2030.

Marketing 52

Marketing Medicine Healthcare Healthcare 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

pharmaphorum

JULY 7, 2022

The latest report – in the Wall Street Journal – says that “advanced talks” are underway that could lead to a $200-plus per share offer that would value Seagen at a massive $40 billion, $10 billion more than earlier estimates.

Pharma 52

Pharma Marketing Sales Medicine 52

European Pharmaceutical Review

NOVEMBER 1, 2023

It is one of the leading causes of death associated with AMR globally. Using this approach, our lead programme – RVX 001, a protein-based vaccine against invasive pneumococcal disease – has been designed with antigens common to all pneumococcus serotypes. Bacterial vaccines in clinical and preclinical development 2021 [Internet].

Safety 115

Safety Marketing Manufacturing Leads 115

MedTechVets

OCTOBER 27, 2023

billion in 2028.” We enjoy leading it in our core but at the same time, companies need to see that we are learners, followers, and committed to the end result.” “The Medical Device field is projected to grow from $455.34 billion in 2021 to $657.98

Medical 59

Medical Ethics Recruitment Marketing 59

Medico Reach

OCTOBER 17, 2022

million by 2028. However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. A lack of good antigens to target in AML is widely believed to have caused this dearth of effective cell therapies.

Marketing 52

Marketing FDA Sales Management 52

European Pharmaceutical Review

FEBRUARY 14, 2023

On the importance of the vaccine, she shared: “Respiratory diseases are a major public health priority given they… are a leading cause of hospitalisation.” According to a recent market research report , a total of five marketed mRNA non-vaccine products will generate over $2 billion by 2028.

Food and Drug Administration 105

Food and Drug Administration Medicine Safety Consulting 105

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

European Pharmaceutical Review

MARCH 9, 2023

There are emerging trends in oncology, with new chemical entities (NCEs) and antibody-drug conjugates (ADC) leading to increased demand for HPAPI manufacturing capabilities. Based on the latest report and data, HPAPI market size is expected to reach $32 billion by 2028.

Safety 98

Safety Pharmacology Training Manufacturing 98

European Pharmaceutical Review

AUGUST 15, 2022

According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. Reuters reported that GSK had acknowledged the fall in supply and said it was pursuing plans to address the deficit.

Manufacturing 98

Manufacturing Pharma Leads Pharmaceutical 98

Medico Reach

JUNE 2, 2022

It also has products from other leading manufacturers. Brasseler USA is one of the leading dental instrumentation companies popular for restorative, orthodontic, endodontic, and oral surgery equipment. It’s one of the leading manufacturers in North America and has catered to the needs of numerous dental clinics and doctors.

Marketing 52

Marketing Manufacturing Distribution Leads 52

European Pharmaceutical Review

OCTOBER 12, 2023

Subject to planning permission, the site is expected to be opened by 2028. At the time of the announcement, Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation, shared that the Novo Nordisk Foundation Cellerator has potential to be “a leading player in Europe and a model for similar facilities around the world”.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Non-small cell lung cancer leads as the indication with the highest number of PROTACs in the pipeline, currently sitting at 11 preclinical candidates.

Competition 59

Competition Safety Patients Pharmaceutical 59

Medico Reach

OCTOBER 17, 2022

million by 2028. However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. The US-based Enovis is leading this new development.

Medical 52

Medical Food and Drug Administration Healthcare Healthcare 52

Quantified

OCTOBER 16, 2023

The Importance of Effective ChatGPT Prompts for Sales Gartner estimates that by 2028, 60% of B2B sales activity will be executed using generative AI platforms like ChatGPT. Example email template prompt: “Draft an email template for following up with leads who attended our recent ABC Widget webinar.

Sales 52

Sales Training Sales Management B2B Sales 52

PM360

APRIL 7, 2023

However, Medicare will only be able to negotiate prices for 10 Part D drugs in 2026, another 15 Part D drugs in 2027, another 15 Part D and Part B drugs in 2028, and another 20 Part D and Part B drugs for 2029 and subsequent years. It’s amazing we still separate the drug costs from overall healthcare costs,” Sontupe says.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Every Ancillary

MAY 14, 2021

That being said, the clinical laboratory market is expected to see growth of nearly 40% by 2028. Delivers real clinical value leading to more effective treatment plans. EKRA has changed the way marketers are compensated by labs, which has led to many abandoning this sector all together. Generous compensation.

Medical sales 52

Medical sales Medical Sales Insurance 52

European Pharmaceutical Review

NOVEMBER 30, 2023

NEWS: Biopharma struggling to find talent with adequate digital skills Looking onward to 2028, the Skills report predicted that, out of a total 81 percent within the cell and gene therapy industry, roles will span support services, R&D and discovery, and bioprocessing.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97